Total Voting Rights Update

RNS Number : 1730U

Shield Therapeutics PLC

31 March 2021

 

Shield Therapeutics plc

("Shield Therapeutics" or the "Company")

Total Voting Rights Update

London, UK, 31 March 2021:  Shield Therapeutics plc (LSE: STX), a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru ® /Accrufer® (ferric maltol), confirms that in accordance with the requirements of the FCA's Disclosure and Transparency Rule 5.6.1, the Company's issued share capital consists of 215,837,965 ordinary shares of 1.5p each in issue, each with equal voting rights. No shares are held in treasury.

The above figure may also be used by shareholders as the denominator in the calculations by which they will determine whether they are required to notify their interest, or a change to their interest, in the Company under the FCA's Disclosure Guidance and Transparency Rules.

For further information, please contact:

Shield Therapeutics plc	[phone]
Tim Watts (CEO) Lucy Huntington-Bailey (Company Secretary and General Counsel)	[phone]
Peel Hunt LLP - Nominated Adviser & Joint Broker			[phone]
James Steel / Christopher Golden
finnCap Ltd - Joint Broker	[phone]
Geoff Nash / Alice Lane / Matthew Radley
Walbrook PR - Financial PR & IR Adviser		[phone]
Paul McManus / Lianne Cawthorne	or [e-mail]

About Shield

Shield is a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru ® /Accrufer ® (ferric maltol), a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia.

Shield's lead product, Feraccru®/Accrufer®, has been approved for use in the United States, European Union, UK and Switzerland and has exclusive IP rights until the mid-2030s. The Group plans to launch Accrufer® in the US during 2021 through a highly experienced sales and marketing team. Feraccru® is already being commercialised in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. Shield also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Feraccru®/Accrufer® in China, Hong Kong, Macau and Taiwan. 

For more information, please visit  www.shieldtherapeutics.com . Follow Shield on Twitter @ShieldTx

 

END

 

 

TVRXFLFXFXLEBBL